blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2141173

EP2141173 - Methods and compositions for the inhibition of gene expression [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  08.11.2013
Database last updated on 28.06.2024
Most recent event   Tooltip17.07.2015Lapse of the patent in a contracting state
New state(s): HU, LU		published on 19.08.2015  [2015/34]
Applicant(s)For all designated states
Pronai Therapeutics, Inc.
4717 Campus Drive, Suite 1100
Kalamazoo, MI 49008-5605 / US
[2010/01]
Inventor(s)01 / Sheikhnehjad, Gholamreza
Pronai Therapeutics Inc.
6394 Bedview Drive
Salie, MI 48176 / US
02 / Sooch, Mina Patel
Pronai Therapeutics Inc.
6894 Lakemont Circle
W. Bloomfield, MI 48323 / US
03 / Goodwin, Neal
34455 East Towle Road
Alta, CA 95701 / US
04 / Olson, David
Pronai Therapeutics Inc.
3303 The Glade Street
Ann Arbor, MI 48103 / US
 [2013/01]
Former [2010/17]01 / Sheikhnehjad, Gholamreza
Pronai Therapeutics Inc. 6394 Bedview Drive
Salie, MI 48176 / US
02 / Sooch, Mina Patel
Pronai Therapeutics Inc. 6894 Lakemont Circle
W. Bloomfield, MI 48323 / US
03 / Goodwin, Neal
34455 East Towle Road
Alta, CA 95701 / US
04 / Olson, David
Pronai Therapeutics Inc. 3303 The Glade Street
Ann Arbor, MI 48103 / US
Former [2010/01]01 / Sheikhnehjad, Gholamreza
Pronai Therapeutics Inc. 6394 Bedview Drive
Salie, MI 48176 / US
02 / Sooch, Mina Patel
Pronai Therapeutics Inc. 6894 Lakemont Circle
W. Bloomfield, MI 48323 / US
03 / Goodwin, Neal
Pronai Therapeutics Inc. 120 109th Avenue
Plainwell, MI 49080 / US
04 / Olson, David
Pronai Therapeutics Inc. 3303 The Glade Street
Ann Arbor, MI 48103 / US
Representative(s)Cohausz & Florack
Patent- & Rechtsanwälte
Partnerschaftsgesellschaft mbB
Bleichstraße 14
40211 Düsseldorf / DE
[N/P]
Former [2013/01]Cohausz & Florack
Patent- und Rechtsanwälte Partnerschaftsgesellschaft Bleichstraße 14
40211 Düsseldorf / DE
Former [2010/01]Cohausz & Florack
Patent- und Rechtsanwälte Bleichstraße 14
40211 Düsseldorf / DE
Application number, filing date09171679.501.06.2005
[2010/01]
Priority number, dateUS2004085801301.06.2004         Original published format: US 858013
US2004085809401.06.2004         Original published format: US 858094
US2004085814501.06.2004         Original published format: US 858145
US2004085814601.06.2004         Original published format: US 858146
US2004085816401.06.2004         Original published format: US 858164
US2004085834101.06.2004         Original published format: US 858341
US20040611974P22.09.2004         Original published format: US 611974 P
US20040637212P17.12.2004         Original published format: US 637212 P
[2010/01]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2141173
Date:06.01.2010
Language:EN
[2010/01]
Type: B1 Patent specification 
No.:EP2141173
Date:02.01.2013
Language:EN
[2013/01]
Search report(s)(Supplementary) European search report - dispatched on:EP20.11.2009
ClassificationIPC:C07H21/02, C07H21/04
[2010/01]
CPC:
C12N15/1135 (EP,US); A61K31/70 (EP,US); A61P35/00 (EP);
A61P35/02 (EP); A61K48/00 (EP,US); C12N2310/11 (EP,US);
C12N2310/3341 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2010/01]
TitleGerman:Verfahren und Zusammensetzungen zur Hemmung der Genexpression[2010/01]
English:Methods and compositions for the inhibition of gene expression[2010/01]
French:Méthodes et compositions inhibant l'expression génique[2010/01]
Examination procedure29.06.2010Examination requested  [2010/31]
22.07.2010Despatch of a communication from the examining division (Time limit: M06)
31.01.2011Reply to a communication from the examining division
12.09.2011Despatch of a communication from the examining division (Time limit: M04)
13.01.2012Reply to a communication from the examining division
06.06.2012Communication of intention to grant the patent
15.10.2012Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
15.10.2012Fee for grant paid
15.10.2012Fee for publishing/printing paid
08.11.2012Communication of intention to grant the patent
Parent application(s)   TooltipEP05804859.6  / EP1773859
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20050804859) is  05.12.2008
Opposition(s)03.10.2013No opposition filed within time limit [2013/50]
Fees paidRenewal fee
29.09.2009Renewal fee patent year 03
29.09.2009Renewal fee patent year 04
29.09.2009Renewal fee patent year 05
22.06.2010Renewal fee patent year 06
15.06.2011Renewal fee patent year 07
19.06.2012Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU01.06.2005
CY02.01.2013
CZ02.01.2013
DK02.01.2013
EE02.01.2013
FI02.01.2013
LT02.01.2013
MC02.01.2013
RO02.01.2013
SI02.01.2013
SK02.01.2013
TR02.01.2013
BG02.04.2013
GR03.04.2013
IS02.05.2013
PT02.05.2013
IE01.06.2013
LU01.06.2013
CH30.06.2013
LI30.06.2013
[2015/34]
Former [2015/32]CY02.01.2013
CZ02.01.2013
DK02.01.2013
EE02.01.2013
FI02.01.2013
LT02.01.2013
MC02.01.2013
RO02.01.2013
SI02.01.2013
SK02.01.2013
TR02.01.2013
BG02.04.2013
GR03.04.2013
IS02.05.2013
PT02.05.2013
IE01.06.2013
CH30.06.2013
LI30.06.2013
Former [2014/20]CY02.01.2013
CZ02.01.2013
DK02.01.2013
EE02.01.2013
FI02.01.2013
LT02.01.2013
MC02.01.2013
RO02.01.2013
SI02.01.2013
SK02.01.2013
BG02.04.2013
GR03.04.2013
IS02.05.2013
PT02.05.2013
IE01.06.2013
CH30.06.2013
LI30.06.2013
Former [2014/08]CY02.01.2013
CZ02.01.2013
DK02.01.2013
EE02.01.2013
FI02.01.2013
LT02.01.2013
MC02.01.2013
RO02.01.2013
SI02.01.2013
SK02.01.2013
BG02.04.2013
GR03.04.2013
IS02.05.2013
PT02.05.2013
Former [2013/52]CY02.01.2013
CZ02.01.2013
DK02.01.2013
EE02.01.2013
FI02.01.2013
LT02.01.2013
RO02.01.2013
SI02.01.2013
SK02.01.2013
BG02.04.2013
GR03.04.2013
IS02.05.2013
PT02.05.2013
Former [2013/49]CZ02.01.2013
DK02.01.2013
EE02.01.2013
FI02.01.2013
LT02.01.2013
RO02.01.2013
SI02.01.2013
SK02.01.2013
BG02.04.2013
GR03.04.2013
IS02.05.2013
PT02.05.2013
Former [2013/48]CZ02.01.2013
DK02.01.2013
EE02.01.2013
FI02.01.2013
LT02.01.2013
SI02.01.2013
BG02.04.2013
GR03.04.2013
IS02.05.2013
PT02.05.2013
Former [2013/40]CZ02.01.2013
FI02.01.2013
LT02.01.2013
SI02.01.2013
BG02.04.2013
GR03.04.2013
IS02.05.2013
PT02.05.2013
Former [2013/37]CZ02.01.2013
FI02.01.2013
LT02.01.2013
SI02.01.2013
BG02.04.2013
GR03.04.2013
IS02.05.2013
Former [2013/35]CZ02.01.2013
LT02.01.2013
SI02.01.2013
BG02.04.2013
IS02.05.2013
Former [2013/34]LT02.01.2013
SI02.01.2013
BG02.04.2013
IS02.05.2013
Former [2013/33]LT02.01.2013
SI02.01.2013
Former [2013/26]SI02.01.2013
Documents cited:Search[A]WO03040182  (VISUFARMA S R L [IT], et al) [A] 1-17 * page 2 - page 5 *;
 [AP]WO2004056971  (GENTA INC [US], et al) [AP] 1-17 * page 13 - page 14 *;
 [AP]WO2004046327  (GENTA SALUS LLC [US]) [AP] 1-17 * abstract *;
 [E]WO2005094783  (NOVOSOM AG [DE], et al) [E] 1-17 * example 6 *
 [X]  - SHEN C ET AL, "Targeting bcl-2 by triplex-forming oligonucleotide - a promising carrier for gene-radiotherapy", CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, (20030201), vol. 18, no. 1, pages 17 - 26, XP002318674 [X] 1-17 * page 18, column 2 - page 19, column 1; figures 1,5 * * page 22, column 1, paragraph 2 - column 2 *

DOI:   http://dx.doi.org/10.1089/108497803321269296
 [X]  - SHEN C ET AL, "Triplex forming oligonucleotide targeted to 3'UTR downregulates the expression of the bcl-2-proto-oncogene in HeLa cells", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, (20010201), vol. 29, no. 3, ISSN 0305-1048, pages 622 - 628, XP002980000 [X] 1-17 * abstract *

DOI:   http://dx.doi.org/10.1093/nar/29.3.622
 [X]  - XODO L E ET AL, "ANTI-GENE STRATEGIES TO DOWN-REGULATE GENE EXPRESSION IN MAMMALIAN CELLS", CURRENT PHARMACEUTICAL DESIGN, BENTHAM SCIENCE PUBLISHERS, SCHIPHOL, NL, (200403), vol. 10, no. 7, ISSN 1381-6128, pages 805 - 819, XP009083431 [X] 1-17 *the whole document, in particular: p. 805, right column, second paragraph, p. 808, right column, second paragraph, fig.5, p. 812, right column, paragraph spanning pages*

DOI:   http://dx.doi.org/10.2174/1381612043452983
 [A]  - REED J C, "Promise and problems of Bcl-2 antisense therapy.", JOURNAL OF THE NATIONAL CANCER INSTITUTE 16 JUL 1997, (19970716), vol. 89, no. 14, ISSN 0027-8874, pages 988 - 990, XP002468189 [A] 1-17 * the whole document *

DOI:   http://dx.doi.org/10.1093/jnci/89.14.988
 [A]  - PUTNAM D A, "ANTISENSE STRATEGIES AND THERAPEUTIC APPLICATIONS", AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, (19960115), vol. 53, no. 2, ISSN 1079-2082, pages 151 - 160,182, XP000603121 [A] 1-17 * the whole document *
 [A]  - WARZOCHA K ET AL, "ANTISENSE STRATEGY: BIOLOGICAL UTILITY AND PROSPECTS IN THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES", LEUKEMIA AND LYMPHOMA, HARWOOD ACADEMIC PUBLISHERS, CHUR, CH, (199701), vol. 24, no. 3/4, ISSN 1042-8194, pages 267 - 281, XP000983227 [A] 1-17 * the whole document *
 [A]  - ZEGLER A ET AL, "Induction of apoptosis in small cell lung cancer cells by antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence", JOURNAL OF THE NATIONAL CANCER INSTITUTE, OXFORD UNIVERSITY PRESS, GB, (19970716), vol. 89, no. 14, ISSN 0027-8874, pages 1027 - 1036, XP002080869 [A] 1-17 * abstract *

DOI:   http://dx.doi.org/10.1093/jnci/89.14.1027
by applicantUS5576208
 US5582986
 US5539082
 US5714331
 US5719262
 US5489677
 US5602240
 US5034506
 US5705188
 WO9730731
 US6169177
 US6008366
 US6383811
 US5844107
 US6077835
 US6177274
 US6287591
 US6447752
 US6447753
 US6440743
 US5108921
 US5416016
 US5635382
 US6291673
 WO02085908
 US6458382
 US6429200
 US6379966
 US6339067
 US5744335
 US5846717
 US6090543
 US6001567
 US5985557
 US5994069
 US5962233
 US5538848
 US5639606
 US5643765
 US5876978
 US5885530
 US4981785
 US6159750
 US5358691
 US5599677
 US5672480
    - J. SAMBROOK, Molecular Cloning: A Laboratory Manual, COLD SPRING HARBOR PRESS, (1989), pages 9.31 - 9.58
    - BOS, CANCER RES., (1989), vol. 49, pages 4682 - 4689
    - DASKA ET AL., ONCOGENE RES., (1990), vol. 5, pages 267 - 275
    - BROWN ET AL., ONCOGENE RES., (1989), vol. 4, pages 243 - 252
    - SAISON-BEHMOARAS ET AL., EMBO J., (1991), vol. 10, pages 1111 - 1116
    - GRAY ET AL., CANCER RES., (1993), vol. 53, pages 577 - 580
    - SCHWAB, PROC. NATL. ACAD. SCI. USA, (1994), vol. 91, pages 10460 - 10464
    - ROUSH, SCIENCE, (1997), vol. 276, pages 1192 - 1194
    - HYNES; STEM, BIOCHIM. ET BIOPHY. ACTA, (1994), vol. 1198, pages 165 - 184
    - DOUGALL ET AL., ONCOGENE, (1994), vol. 9, pages 2109 - 2123
    - LEE ET AL., NATURE, (1995), vol. 378, pages 394 - 398
    - COUSSENS ET AL., SCIENCE, (1985), vol. 230, pages 1132 - 1139
    - YAMAMOTO ET AL., NATURE, (1986), vol. 319, pages 230 - 234
    - HYNES; STEEN, BIOCHIM. ET BIOPHYS. ACTA, (1994), vol. 1198, pages 165 - 184
    - DIFIORE ET AL., SCIENCE, (1987), vol. 237, pages 178 - 182
    - HUDZIAK, PROC. NATL. ACAD. SCI. USA, (1987), vol. 84, pages 7159 - 7163
    - SLAMON ET AL., SCIENCE, (1987), vol. 235, pages 177 - 182
    - SLAMON ET AL., SCIENCE, (1989), vol. 244, pages 707 - 712
    - TAN, CANCER RES., (1997), vol. 57, page 1199
    - COHEN ET AL., J. BIOL. CHEM., (1996), vol. 271, page 30897
    - CHANG ET AL., ONCOGENE, (1997), vol. 14, page 561
    - WEINER ET AL., J. HEMATOTHERAPY, (1995), vol. 4, page 471
    - UENO ET AL., ONCOGONE, (1997), vol. 15, page 953
    - ZHANG ET AL., ONCOGENE, (1996), vol. 12, page 571
    - WITTERS ET AL., BREAST CANCER RES. AND TREATMENT, (1997), vol. 42, page 1
    - EBBINGHAUS ET AL., J. CLIN. INVEST., (1993), vol. 92, page 2433
    - PORUMB ET AL., CANCER RES., vol. 56, page 515
    - JUHL ET AL., J. BIOL. CHEM., (1997), vol. 272, page 29482
    - PEGUES ET AL., CANCER LETT., (1997), vol. 117, page 73
    - CASALINI ET AL., INT. J. CANCER, (1997), vol. 72, page 631
    - COLOMER ET AL., BR. J. CANCER, (1994), vol. 70, page 819
    - WIECHEN ET AL., INT. J. CANCER, (1995), vol. 63, page 604
    - BERTRAM ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., (1994), vol. 200, page 661
    - LIU ET AL., ANTISENSE AND NUCLEIC ACID DRUG DEVELOP., (1996), vol. 6, page 9
    - VAUGHN ET AL., NUC. ACIDS. RES., (1996), vol. 24, page 4558
    - BRYSCH ET AL., CANCER GENE THER., (1994), vol. 1, page 99
    - HAREL-BELLAN ET AL., J. IMMUN., (1988), vol. 140, pages 2431 - 2435
    - MARCU ET AL., ANN. REV. BIOCHEM., (1992), vol. 61, pages 809 - 860
    - WATT ET AL., NATURE, (1983), vol. 303, pages 725 - 728
    - BATTEY ET AL., CELL, (1983), vol. 34, pages 779 - 787
    - TSUJIMOTO ET AL., SCIENCE, (1985), vol. 228, pages 1440 - 1443
    - REED ET AL., CANCER RES., (1991), vol. 51, page 6529
    - YUNIS ET AL., NEW ENGLAND J. MED., vol. 320, page 1047
    - CAMPOS ET AL., BLOOD, (1993), vol. 81, pages 3091 - 3096
    - MCDONNELL, CANCER RES., (1992), vol. 52, pages 6940 - 6944
    - LU ET AL., INT. J CANCER, (1993), vol. 53, pages 29 - 35
    - BONNER ET AL., LAB INVEST., (1993), vol. 68, page 43A
    - CAMPBELL ET AL., PROG. GROWTH FACTOR RES., (1989), vol. 1, page 13
    - MASSAGUE, J. BIOL. CHEM., (1990), vol. 265, pages 21393 - 21396
    - PANDIELLA ET AL., PROC. NATL. ACAD. SCI. USA, (1990), vol. 88, pages 1726 - 1730
    - PANDIELLA ET AL., J. BIOL. CHEM., (1991), vol. 266, pages 5769 - 5773
    - WILDING ET AL., THE PROSTATE, (1989), vol. 15, pages 1 - 12
    - SANDGREN ET AL., CELL, (1990), vol. 61, pages 1121 - 1135
    - PULCIANI ET AL., NATURE, (1982), vol. 300, page 539
    - FEIG ET AL., SCIENCE, (1984), vol. 223, page 698
    - RODENHUIS ET AL., NEW ENG. J. MED., (1987), vol. 317, page 929
    - YANEZ ET AL., ONCOGENE, (1987), vol. 1, page 315
    - EHRLICK ET AL., SCIENCE, (1981), vol. 212, pages 1350 - 1357
    - DOERFLER, ANNU. REV. BIOCHEM., (1984), vol. 52, pages 93 - 124
    - CHRISTMAN, CURR. TOP. MICROBIOL. IMRNUNOL., (1988), vol. 108, pages 49 - 78
    - CEDAR, CELL, (1988), vol. 34, pages 5503 - 5513
    - TATE ET AL., CURR. OPIN. GENET. DEV., (1993), vol. 3, pages 225 - 231
    - CHRISTMAN, Virus Strategies, VCH, (1993), pages 319 - 333
    - CHRISTMAN ET AL., PROC. NATL. ACAD. SCI. USA, (1995), vol. 92, pages 7347 - 7351
    - JONES ET AL., ADV. CANCER RES, (1983), vol. 40, pages 1 - 30
    - NAMBU, JPN. J. CANCER (GANN), (1987), vol. 78, pages 696 - 704
    - FEINBERG ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., (1983), vol. 111, pages 47 - 54
    - CHEAH ET AL., JNCI, (1984), vol. 73, pages 1057 - 1063
    - BHAVE ET AL., CARCINOGENESIS (LOND), (1988), vol. 9, pages 343 - 348
    - GOETZ ET AL., SCIENCE, (1985), vol. 228, pages 187 - 290
    - WAINFAN ET AL., CANCER RES., (1992), vol. 52, pages 2071S - 2077S
    - DIZIK ET AL., CARCINOGENESIS, (1991), vol. 12, pages 1307 - 1312
    - WAINFAN ET AL., CANCER RES., (1989), vol. 49, pages 4094 - 4097
    - NIELSEN ET AL., SCIENCE, (1991), vol. 254, page 1497
    - MARTIN ET AL., HELV. CHIM. ACTA, (1995), vol. 78, page 486
    - ZUCKENNANN ET AL., J. MED. CHEM., (1994), vol. 37, pages 2678 - 85
    - LAM, ANTICANCER DRUG DES., (1997), vol. 12, page 145
    - DEWITT ET AL., PROC. NATL. ACAD. SCI. U.S.A., (1993), vol. 90, page 6909
    - ERB ET AL., PROC. NAD. ACAD. SCI. USA, (1994), vol. 91, page 11422
    - ZUCKERMANN ET AL., J. MED. CHEM., (1994), vol. 37, page 2678
    - CHO ET AL., SCIENCE, (1993), vol. 261, page 1303
    - CARRELL ET AL., ANGEW. CHEM. INT. ED. ENGL., (1994), vol. 33, page 2059
    - CARELL ET AL., ANGEW. CHEM. INT. ED. ENGL., (1994), vol. 33, page 2061
    - GALLOP ET AL., J. MED. CHEM., (1994), vol. 37, page 1233
    - HOUGHTEN, BIOTECHNIQUES, (1992), vol. 13, pages 412 - 421
    - LAM, NATURE, (1991), vol. 354, pages 82 - 84
    - FODOR, NATURE, (1993), vol. 364, pages 555 - 556
    - CULL ET AL., PROC. NAD. ACAD. SCI. USA, (1992), vol. 89, page 18651869
    - SCOTT; SMITH, SCIENCE, (1990), vol. 249, pages 386 - 390
    - DEVLIN, SCIENCE, (1990), vol. 249, pages 404 - 406
    - CWIRLA ET AL., PROC. NATL. ACAD. SCI., (1990), vol. 87, pages 6378 - 6382
    - FELICI, J. MOL. BIOL., (1991), vol. 222, page 301
    - SICILIANO MJ; BARKER PE; CAILLEAU R., "Mutually exclusive genetic signatures of human breast tumor cell lines with a common chromosomal marker", CANCER RES., (197903), vol. 39, no. 3, pages 919 - 22
    - CALLEAU R; OLIVE M; CRUCIGER QV., "Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization", IN VITRO, (197811), vol. 14, no. 11, pages 911 - 5
    - CRUCIGER QV; PATHAK S; CALLEAU R, "Human breast carcinomas: marker chromosomes involving lq in seven cases", CYTOGENET CELL GENET., (1976), vol. 17, no. 4, pages 231 - 5
    - SATYA-PRAKASH KL ET AL., "Cytogenetic analysis on eight human breast tumor cell lines: high frequencies of lq, 11q and HeLa-like marker chromosomes", CANCER GENET CYTOGENET, (198101), vol. 3, no. 1, pages 61 - 73
    - SOULE HD ET AL., "Ahuman cell line from a pleural effusion derived from a breast carcinoma", J. NATL. CANCER INST., (1973), vol. 51, pages 1409 - 1416
    - LANDERS JE ET AL., "Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein", CANCER RES., (1997), vol. 57, pages 3562 - 3568
    - BACUS SS ET AL., "Differentiation of cultured human cancer cells (AU-565 and MCF7) associated with loss of cell surface HER-2/neu oligonucleotide", MOL. CARCINOG, (1990), vol. 3, pages 350 - 362
    - SANTNER SJ ET AL., "Malignant MCF10OCA1 cell lines derived from premalignant human breast epithelial MCF10AT cells", BREAST CANCER RESEARCH AND TREATMENT, (2001), vol. 65, pages 101 - 110
    - OWENS RB, "Glandular epithelial cells from mice: a method for selective cultivation", J. NATL. CANCER INST., (1974), vol. 52, pages 1375 - 1378
    - OWENS RB ET AL., "Epithelial cell cultures from normal glandular tissue of mice", J. NATL. CANCER INST., (1974), vol. 53, pages 261 - 269
    - YINGLING JM ET AL., "Mammalian dwarfins are phosphorylated in response to transforming growth factor beta and are implicated in control of cell growth", PROC. NATL. ACAD. SCI. USA, (1996), vol. 93, pages 8940 - 8944
    - TAN MH ET AL., "Characterization of a new primary human pancreatic tumor line", CANCER INVEST., (1986), vol. 4, pages 15 - 23
    - LOOR R ET AL., "Use of pancreas-specific antigen in immunodiagnosis of pancreatic cancer", CLIN. LAB. MED., (1982), vol. 2, pages 567 - 578
    - LAN MS ET AL., "Polypeptide core of a human pancreatic tumor mucin antigen", CANCER RES., (1990), vol. 50, pages 2997 - 3001
    - CHAMBERS JA; HARRIS A, "Expression of the cystic fibrosis gene and the major pancreatic mucin gene, MUC1, in human ductal epithelial cells", J. CELL SCI., (1993), vol. 105, pages 417 - 422
    - KEYDAR I ET AL., "Establishment and characterization of a cell line of human breast carcinoma origin", EUR. J. CANCER, (1979), vol. 15, pages 659 - 670
    - JUDGE SM; CHATTERTON RT JR, "Progesterone-specific stimulation of triglyceride biosynthesis in a breast cancer cell line (T-47D)", CANCER RES., (1983), vol. 43, pages 4407 - 4412
    - LAMP SJ ET AL., "Calcitonin induction of a persistent activated state of adenylate cyclase in human breast cancer cells (T-47D)", J. BIOL. CHEM., (1981), vol. 256, pages 12269 - 12274
    - SHER E ET AL., "Whole-cell uptake and nuclear localization of 1,25-dihydroxy-cholecalciferol by breast cancer cells (T-47D) in culture", BIOCHEM. J., (1981), vol. 200, pages 315 - 320
    - FREAKE HC ET AL., "1,25-Dihydroxyvitamin D3 specifically binds to a human breast cancer cell line (T-47D) and stimulates growth", BIOCHEM. BIOPHYS. RES. COMMUN., (1981), vol. 101, pages 1131 - 1138
    - FAUST JB; MEEKER TC, "Amplification and expression of the bcl-1 gene in human solid tumor cell lines", CANCER RES., (1992), vol. 52, pages 2460 - 2463
    - HUGUET EL ET AL., "Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast cell lines and normal and disease states of human breast tissue", CANCER RES., (1994), vol. 54, pages 2615 - 2621
    - LASFARGUES EY ET AL., "Isolation of two human tumor epithelial cell lines from solid breast carcinomas", J. NATL. CANCER INST., (1978), vol. 61, pages 967 - 978
    - LASFARGUES EY ET AL., "A human breast tumor cell line (BT-474) that supports mouse mammary tumor virus replication", IN VITRO, (1979), vol. 15, pages 723 - 729
    - LITTLEWOOD-EVANS AJ ET AL., "The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma", CANCER RES., (1997), vol. 57, pages 5386 - 5390
    - MOHAMMAD RM ET AL., "A unique EBV-Negative Low Grade Lymphoma Line (WSU-FSCCL) Exhibiting both t(14;18) and t(8;11)", CANCER GENET CYTOGENET, (1993), vol. 70, pages 62 - 67
    - YANG ET AL., CANCER RESEARCH, (1999), vol. 59, pages 781 - 786
    - GLINSKII ET AL., CANCER RESEARCH, (2003), vol. 63, pages 4239 - 4243
    - KALIKIN ET AL., CANCER BIOLOGY AND THERAPY, (2003), vol. 2, no. 6, pages 17 - 21
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.